Development of New Methodology to Optimize Peptide-based Drug Discovery

• Research unit: INNOSUISSE
• Project number: 8557.1;6 LSPP-LS

Short description (English)

Development of New Methodology to Optimize Peptide-based Drug Discovery

Short description (French)

Development of New Methodology to Optimize Peptide-based Drug Discovery

Abstract (English)

Dr Hartley's lab is a world leader in the field of peptide and protein engineering. Recent work has focussed on adapting molecular diversity technologies such as phage display in order to develop proteins and peptides as candidate medicines. The project aims are (i) to develop new molecular diversity strategies related to peptide drug discovery, and (ii) to test them, alongside existing approaches, as tools to develop novel peptide-based drugs. Evaluation of the approaches will be performed in collaboration with GENKYOTEX, a CTI start-up company whose mission is to develop new drugs that inhibit NOX enzymes. Such drugs could be used to treat diseases for which effective therapies are currently lacking.

Abstract (French)

Dr Hartley's lab is a world leader in the field of peptide and protein engineering. Recent work has focussed on adapting molecular diversity technologies such as phage display in order to develop proteins and peptides as candidate medicines. The project aims are (i) to develop new molecular diversity strategies related to peptide drug discovery, and (ii) to test them, alongside existing approaches, as tools to develop novel peptide-based drugs. Evaluation of the approaches will be performed in collaboration with GENKYOTEX, a CTI start-up company whose mission is to develop new drugs that inhibit NOX enzymes. Such drugs could be used to treat diseases for which effective therapies are currently lacking.